RT Journal Article SR Electronic T1 Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.10.21249151 DO 10.1101/2021.01.10.21249151 A1 Jennifer R. Hamilton A1 Elizabeth C. Stahl A1 Connor A. Tsuchida A1 Enrique Lin-Shiao A1 C. Kimberly Tsui A1 Kathleen Pestal A1 Holly K. Gildea A1 Lea B. Witkowsky A1 Erica A. Moehle A1 Shana L. McDevitt A1 Matthew McElroy A1 Amanda Keller A1 Iman Sylvain A1 Ariana Hirsh A1 Alison Ciling A1 Alexander J. Ehrenberg A1 IGI SARS-CoV-2 consortium A1 Bradley R. Ringeisen A1 Garth Huberty A1 Fyodor D. Urnov A1 Petros Giannikopoulos A1 Jennifer A. Doudna YR 2021 UL http://medrxiv.org/content/early/2021/01/11/2021.01.10.21249151.abstract AB Saliva is an attractive specimen type for asymptomatic surveillance of COVID-19 in large populations due to its ease of collection and its demonstrated utility for detecting RNA from SARS-CoV-2. Multiple saliva-based viral detection protocols use a direct-to-RT-qPCR approach that eliminates nucleic acid extraction but can reduce viral RNA detection sensitivity. To improve test sensitivity while maintaining speed, we developed a robotic nucleic acid extraction method for detecting SARS-CoV-2 RNA in saliva samples with high throughput. Using this assay, the Free Asymptomatic Saliva Testing (IGI-FAST) research study on the UC Berkeley campus conducted 11,971 tests on supervised self-collected saliva samples and identified rare positive specimens containing SARS-CoV-2 RNA during a time of low infection prevalence. In an attempt to increase testing capacity, we further adapted our robotic extraction assay to process pooled saliva samples. We also benchmarked our assay against the gold standard, nasopharyngeal swab specimens. Finally, we designed and validated a RT-qPCR test suitable for saliva self-collection. These results establish a robotic extraction-based procedure for rapid PCR-based saliva testing that is suitable for samples from both symptomatic and asymptomatic individuals.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis study was funded by gifts from the Packard Foundation and the Curci Foundation to the Innovative Genomics Institute at UC Berkeley. J.R.H. is a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research. K.P. is a Cancer Research Institute Irvington Fellow supported by the Cancer Research Institute. H.K.G is supported by NSF Grant # DGE175814 and NIA 1F99AG068343-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California, Berkeley Committee for Protection of Human Subjects (CPHS) provided approval for the IGI-FAST research study (IRB submission # 2020-05-13336). Descriptive statistics for patient samples used in this manuscript come from de-identified datasets in accordance with human subjects protections, as approved by UC Berkeley's CPHS. While Institutional Review Board (IRB) approval is required for any research using human subjects, clinical laboratory activities exclusively supporting CLIA-certified clinical operations do not. These activities are governed by CMS and HIPAA legislation. In order to publish our data in this manuscript as results of developing a testing workstream, we sought IRB approval through UC Berkeley's CPHS (IRB submission # 2020-04-13177). The Washington Hospital Healthcare System (WHHS) determined the NP/saliva comparison study was not considered research by WHHS IRB. As such, a consent form that was approved by WHHS compliance and the appropriate WHHS legal representative was sufficient to share de-identified samples. A letter detailing this exemption is presented in Supplemental Figure 6.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for the current study are available upon reasonable request.